The long-term impact of oxaliplatin chemotherapy on rodent cognition and peripheral neuropathy.
Chemotherapy treatment is associated with cognitive dysfunction in cancer survivors after treatment completion. The duration of these impairments is unclear. Therefore this paper aims to evaluate the lasting impact of varying doses of the chemotherapy oxaliplatin (OX) on cognition and peripheral neuropathy. In Experiment 1 rats were treated once a week for 3 weeks with either physiological saline (control) or 6 mg/kg OX i.p. and were assessed for peripheral neuropathy, using von Frey filaments, and cognitive function, using novel object and location recognition, up to 2 weeks after treatment completion. For Experiment 2 rats received 3 weekly i.p. injections of either physiological saline (control), 0.6 mg/kg, 2mg/kg or 6 mg/kg OX and assessed for peripheral neuropathy and cognitive function up to 11 months after treatment completion. Systemic OX treatment induced lasting effects on cognitive function at 11 months after treatment, and peripheral neuropathy at 1 month after treatment and these were dose dependent; higher doses of OX resulted in worse cognitive outcomes and more severe peripheral neuropathy.
School of Psychology, The University of Sydney, Australia. Electronic address: joanna.fardell@sydney.edu.au.
Joanna E
JE
Fardell
Concord Cancer Centre, Concord General Repatriation Hospital, Sydney Medical School, The University of Sydney. Electronic address: janette.vardy@sydney.edu.au.
Janette
J
Vardy
Discipline of Addiction Medicine, Central Clinical School, Sydney Medical School, The University of Sydney. Electronic address: lauren.monds@sydney.edu.au.
Lauren A
LA
Monds
School of Psychology, The University of Sydney, Australia. Electronic address: i.johnston@sydney.edu.au.
Ian N
IN
Johnston
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D003072:Cognition Disorders / Q000139:chemically induced*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006930:Hyperalgesia / Q000139:chemically induced / Q000503:physiopathology; D008297:Male; D009944:Organoplatinum Compounds / Q000633:toxicity*; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000503:physiopathology; D017208:Rats, Wistar; D021641:Recognition, Psychology / Q000187:drug effects; D013997:Time Factors; D014110:Touch
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin
Chemotherapy; Cognition; Mechanical allodynia; Oxaliplatin; Peripheral neuropathy; Rat